PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures as well as syngeneic tumor models treated with Newcastle disease virus (NDV) to ide...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of clinical investigation Ročník 128; číslo 4; s. 1413 - 1428
Hlavní autori:	Zamarin, Dmitriy, Ricca, Jacob M., Sadekova, Svetlana, Oseledchyk, Anton, Yu, Ying, Blumenschein, Wendy M., Wong, Jerelyn, Gigoux, Mathieu, Merghoub, Taha, Wolchok, Jedd D.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Society for Clinical Investigation 01.04.2018
Predmet:	Analysis Apoptosis Biomedical research Cancer therapies Care and treatment Cell death Clinical trials Drug therapy Genes Health aspects Immunotherapy Infections Interferon Ligands Lymphocytes Lymphocytes T Melanoma Metastases Metastasis Newcastle disease Oncolysis Patient outcomes PD-1 protein PD-L1 protein Skin cancer Therapeutic targets Tumors Viruses United States Oncology Immunology Gene therapy T cells Immunotherapy
ISSN:	0021-9738, 1558-8238, 1558-8238
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!